Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really under-noticed, I think we're going to have a major run!
$$ GOING TO OPEN STRONG TOMORROW $$$ GO ABPI !!!
$UNDERVALUED PLAY HERE!
Going to close strong tomorrow, I can feel it!
Great close, tomorrow should be good. #ebolastock ftw
Nice....I feel the same way. Looking for a nice rip here!!
Made some calls around. Word is with the current worsening ebola scare (now in CT some say) some of the penny promotion sites want to run this sector 10,000 to 15,000 percent! Can you imagine!!! I am currently in a stock (FITX) that was pushed from triple zero's to .11 at the high, now at .04ish. Either way a HUGE run by these promotion sites. So now is the time to get into this little gem ABPI!!!
$$$$$$ ABPI, THIN TILL COPPER $$$$$$
Nice .01 gone!!!!! Weeeeeeeee!!!
1'S GETTING TAKEN OUT, NEXT 1000% RUN TODAY.
Getting closer by the minute!!!
ABPI $$$$$$$$
8'S GONE. .01 IS UP, IS IT TIME TO FLY?
Looks like the smart people are loading! This won't be down here for much longer.... Goin back to a penny on the next slap!
Come on with the afternoon rush!!! This baby got wings!!!
Looking good here!!! Come on with the Nickle!!!!
Go. ABPI
Keep moving up that green and the volume will come to ABPI.
Keep moving up that green and the volume will come to ABPI.
$ABPI
Bought some at .008! ;) made it more thin
Good luck! But rofl I heard people use EBOLO instead of yolo.
Theres your proof of EBOLA and ABPI link. Its time to run baby
Slaps and bids coming in... lets gooooo!!
$$$ ABPI $$$
If we break thru the pivot point of .0085 then next resistance is at .0116 then .017. The engine is priming just needs alil volume.
Hell yes!!! Folks know this has wings!!
Go ABPI $$$$$$
ABPI EBOLA NEWS LINK!
anyone think we see an update from this 2012 article?
http://www.businesswire.com/news/home/20120423005490/en/Biovest-U.S.-Army-Enter-Collaborative-Agreement-Develop#.VDvRJ_l_lC0
No one is buying today. Slow day. Hopefully we hold at these levels. L2 anyone? Thanks
Don't know about .50 - .75 but .05 not out of the question.
$ABPI !!!! $$$$$
Let's see a nickle! !!
Go ABPI !!!
Great find Frankie!!! This company is DEFINITELY GOING UP! Ebola cases are popping up everywhere...
Right, I see that but it is not really specific to anything breakthrough or even closely remote. Bid is currently below the close of yesterday. Expecting another 50% decline today
Lets make it rain, Rainer!!!!! ABPI ready for liftoff!!!
ABPI got mention on IHUB NEWSWIRE this am also!!! Looking good....
Me either but liking the attention! ! Come on ABPI!!
WOW!! Nice find.
None of the sub penny stocks are really doing ebola but there's about 25 of them where traders want to make the connection. This ticker is no different imo. On watch for a bounce here.
Hollow-Fiber Coming Soon
http://hollow-fiber.com/
Website just created 7-24-2014 according to godaddy
https://who.godaddy.com/whoisstd.aspx?domain=hollow-fiber.com&prog_id=GoDaddy
Looks like something coming, possibly HUGE
I don't wanna be a Debbie downer because this stock has a lot going for it at this time but I have yet to read anything related to this company and Ebola. I'm guessing and hoping that they will eventually. The only thing I have seen related to ABPI and Ebola is from an organization in the United Kingdom that abbreviated ABPI. Please tell me I'm wrong. They company we are invested in is in Tampa.
Gains on gains on gains.... Round 3 comin up! These Ebola stocks are golden because they're actually working on something related to a worldwide issue. This is a real company with a purpose.
ABPI is making moves..... $$$$
We have good company in this ticker, Frankie. Big positions taken and held, not for no good reason!!!
$ABPI LONG FOR THE WIN $$$$$$$
I agree K4!!!! Much more green to come!!!!
GO $ABPI
Everyone here is holding for the monster run coming....not everyone knows about the $ABPI Ebola connection.
KABOOOOOOM!!!
I'm holding. Don't get what happened here today.
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
677
|
Created
|
09/03/05
|
Type
|
Free
|
Moderators |
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have entered into a Cooperative Research and Development Agreement (CRADA) to further develop Biovest’s hollow fiber perfusion bioreactors as a flexible and modular manufacturing platform for the rapid, robust and cost-effective production of medical countermeasures to emerging and genetically engineered infectious diseases. This CRADA utilizes Biovest’s hollow fiber technology for production of vaccines, virus-like particles (VLPs) and antibodies for treatment and prevention of filovirus diseases including those caused by Ebola and Marburg viruses.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID”
According to Biovest’s consulting medical advisor, J. David Gangemi, Ph.D., Professor Emeritus, Microbiology and Molecular Medicine, Clemson University, “Biovest’s collaboration with USAMRIID is part of a large U.S. government priority investment to become fully prepared for the swift and efficient delivery of medical countermeasures to highly infectious agents including avian and swine influenza, and other emerging diseases. Expanding on the positive influenza virus data generated under Biovest’s CRADA with the Naval Health Research Center, our collaboration with Army’s infectious disease research team aims to demonstrate the utility and agility of Biovest’s hollow fiber bioreactors to propagate infectious virus for vaccine production and to validate the production of VLPs and virus neutralizing antibodies.”
Biovest’s patented hollow fiber bioreactor systems are compact, scalable and economical for large-scale virus and antibody production. In contrast to other systems, Biovest’s technology provides multiple benefits including: 1) controlled culture conditions with high cell density attained; 2) space efficiency and high-yield production; and 3) selective dilution/removal of inhibitory byproducts.
“Our instrumentation is uniquely designed for the commercial manufacture of personalized medicines and vaccines. This vast potential is now being evaluated in three very important collaborations with the Naval Health Research Center, Max Planck Institute and USAMRIID,” stated, Biovest’s Chief Science Officer, Mark Hirschel, Ph.D. “And we are continuing to pursue other strategic partnerships within the U.S. Department of Defense and with other leading research institutions worldwide to establish Biovest’s biomanufacturing technology as an optimal cell culture platform for the production of many kinds of cell-based biologic therapies.”
AutovaxID® is an automated, self-contained, scalable system that employs a single-use, hollow-fiber bioreactor for cell expansion. Since it is functionally closed, computer-controlled and fully-automated, operation of the AutovaxID requires limited supervision and minimal manpower compared to other systems. The AutovaxID is a flexible system, uniquely designed to address a variety of biotechnology and pharmaceutical applications.
Been in development for over 2 YEARS. This company has been in the development a treatment for over 2 years, much more than those JUST OTC companies coming into the market just now.MINNEAPOLIS & TAMPA, Fla.--(BUSINESS WIRE)--
Biovest International, Inc. (“Biovest”), a leader and a pioneer in the development of personalized cancer immunotherapies, today announced that Biovest’s Chief Executive Officer, Carlos F. Santos, Ph.D., will deliver the keynote presentation at the Phacilitate Immunotherapy Forum (part of Phacilitate’s Washington Bioleaders 2014 Conference) taking place at the Grand Hyatt Hotel on January 27-29, 2014 in Washington, D.C. The keynote presentation on Monday, January 27, 2014 is titled “The Integration of Clinical Bioinformatics, Automated Cell Culture, and Automated Manufacturing for the Rapid Development of Personalized Lymphoma Vaccines”, and Dr. Santos will be a panelist for the corresponding discussion session. Dr. Santos will serve as the chair and moderator of the Tuesday, January 28, 2014 morning plenary session of the Immunotherapy Forum. He will also make a presentation titled "Case Study: Making the Personal Affordable: Efficient Manufacture of Autologous Cancer Immunotherapies”, and will act as an informal panelist for the panel discussion to follow. On the final day of the Conference, January 29, 2014, Dr. Santos will present "Case Studies of Personalized Immunotherapies in Development – Examining Trial Designs and Biomarker R&D Strategies – Case Study 3”.
“This forum provides us an excellent opportunity to advance personalized immunotherapy and interact with leaders in the fields of cancer vaccines, cell and gene therapy, and biologics manufacturing,” said Dr. Santos. “At Biovest, we have developed a highly personalized, tumor-matched cancer vaccine (BiovaxID; dasiprotimut-T) to fight non-Hodgkin’s lymphoma. As part of our efforts in bringing this vaccine to market, we have also pioneered highly automated systems for biomanufacturing of personalized medicines. We believe these advances, together with the clinical informatics and biomarker data which accompanies each of our vaccines, will ultimately make cancer vaccines much more accessible for patients diagnosed with non-Hodgkin’s lymphoma.”
Robert E. Farrell, J.D., Biovest’s Chief Financial Officer, will be presenting at the Personalized Medicines World Conference of Silicon Valley on January 27-28, 2014. Mr. Farrell’s presentation, “Automated Systems for Personal-Scale Manufacture of Commercial Cancer Vaccines“, will take place on January 28, 2014 at 8:45 AM PST at the Computer History Museum in Mountain View, CA. Mr. Farrell stated, “both of these conferences will present substantial exposure for Biovest’s immunotherapy program and provide an exciting opportunity to network with the biotechnology, personalized medicine, active immunotherapy, and investment communities. They provide outstanding venues in which to display our pioneering advances in personalized cancer vaccines.”
About Biovest International, Inc.
Biovest International, Inc. develops autologous active immunotherapies (personalized cancer vaccines) to treat B-cell non-Hodgkin’s lymphomas, which are cancers of the immune system. The Company’s lead personalized cancer vaccine candidate, BiovaxID, has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxID’s ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxID.
Accentia Biopharmaceuticals, Inc., a biotechnology company, engages in the development and commercialization of biopharmaceutical products in the United States. It develops Cyrevia as a system of care for the treatment of autoimmune diseases; SinuNasal lavage system as a medical device for the treatment of chronic sinusitis; and BiovaxID as a personalized therapeutic cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, mantle cell lymphoma, and other B-cell cancers. The company also sells hollow-fiber perfusion instruments used for the production of significant quantities of cell culture products, including AutovaxID, an automated cell culture production instrument an instrument for the production of cancer vaccines and other personalized medicines; Primer HF, a hollow-fiber cell culture system for producing small quantities of monoclonal antibody; miniMax and Maximizer for use in the production of mammalian cell secreted proteins; XCellerator, a self-standing floor system to support production protein; Multi-6, a cell culture system for producing six monoclonal antibodies; and hollow-fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. It has collaboration with the United States Department of Defense to develop AutovaxID and to explore potential production of additional vaccines, including vaccines for viral indications, such as influenza. The company was founded in 2002 and is headquartered in Tampa, Florida.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |